
- 208 pages
- English
- PDF
- Available on iOS & Android
About this book
The articles that appear in Antiviral Drugs - Aspects of Clinical Use and Recent Advances cover several topics that reflect the varied mechanisms of viral disease pathogenesis and treatment. Clinical management and new developments in the treatment of virus-related diseases are the two main sections of the book. The first part reviews the treatment of hepatitis C virus infection, the management of virus-related acute retinal necrosis, the use of leflunomide therapy in renal transplant patients, and mathematical modeling of HIV-1 treatment responses. Basic research topics are dealt with in the second half of the book. New developments in the treatment of the influenza virus, the use of animal models for HIV-1 drug development, the use of single chain camelid antibodies against negative strand RNA viruses, countering norovirus infection, and the use of plant extracts to treat herpes simplex virus infection are described. The content of the book is not intended to be comprehensive, but aims to provide the reader with insights into selected aspects of established and new viral therapies.
Frequently asked questions
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Information
Table of contents
- Antiviral Drugs - Aspects of Clinical Use and Recent Advances
- Contents
- Preface
- Part 1 Clinical Management of Viral Infection
- Part 2 Developing New Antivirals